Brief: GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA
17/06/2026 16:10
BRIEF-GSK Says cUTI Oral Antibiotic Tebipenem Approved By US FDA June 17 (Reuters) - GSK plc GSK.L:
GSK PLC - CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA
GSK - TEBIPENEM PIVOXIL EXPECTED TO BE AVAILABLE IN US BY END OF 2026
Source text: ID:nRSQ7248Ia
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)